Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
64.26 ^USD	+0.28%		-2.16%	-20.68%

May. 31	Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival	RE
May. 31	Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival	May. 31	RE
Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients	May. 31	MT
Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study	May. 31	CI
Gilead Sciences Says Phase 3 Trial in Urothelial Cancer Misses Primary Target	May. 30	MT
Gilead's Trodelvy fails to meet main goal in late-stage study	May. 30	RE
Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study	May. 30	CI
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	May. 09	CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV	Apr. 26	CI
News Highlights : Top Company News of the Day - Friday at 1 AM ET	Apr. 26	DJ
News Highlights : Top Company News of the Day - Thursday at 11 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 9 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 5 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 7 PM ET	Apr. 25	DJ
Gilead Sciences Q1 Tops Estimates, Updates Outlook	Apr. 25	MT
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges	Apr. 25	DJ
(GILD) GILEAD SCIENCES Forecasts Fiscal Year 2024 EPS Range $3.45 - $3.85	Apr. 25	MT
Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.69B, vs. Street Est of $6.348B	Apr. 25	MT
Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.	Apr. 25	CI
Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Highlights

Filters